In addition, about 30% of HNSCC or skin cancer cases show overexpression of JAG1 or JAG2 [87], which may be in line with the activation of the Notch pathway at least in some cases [88,89], especially aggressive, late-stage cancers, and is associated with poor patient outcome [88,89]. The gene discussed is JAG2; the disease is cancer.